

Borstkanker

DAG	TITEL	TIJD	LOCATIE
VRIJDAG 27.09.19	Multidisciplinary management of germline and somatic gene alterations in patients with metastatic breast cancer	14.15 -15.15	Pamplona Auditorium (Hal 2)
	Biosimilars use in oncology: clarifying concepts	16.00 -17.30	Valencia Auditorium (Hal 5)
	Is there a role for the addition of platinum-based chemotherapy to standard neoadjuvant chemotherapy in triple negative breast cancer (TNBC)?	16.15 -17.15	Granada Auditorium (Hal 3)
	Partial breast radiation therapy: Which patients, when, and with what technique?	16.15 -17.25	Alicante Auditorium (Hal 3)
<i>Pfizer sponsored symposium:</i>	Real world data in oncology: It's growing role in research and patient care	18:00 -20:00	Alicante Auditorium (Hal 3)
<i>Roche sponsored symposium:</i>	Multi-disciplinary perspectives on optimising patient outcomes in HER2-positive eBC	18:00 - 19:30	Cordoba Auditorium (Hal 7)
ZATERDAG 28.09.19	Tackling the treatment options in triple negative metastatic breast cancer	08.45 - 09.45	Salamanca Auditorium (Hal 3)
	Proffered Paper - Breast cancer, metastatic	10.15 -11.45	Barcelona Auditorium (Hal 2)
<i>Pfizer sponsored symposium:</i>	From clinical trials to practice: Changing the trajectory for patients with breast cancer	13.00 -14.30	Pamplona Auditorium (Hal 2)
<i>Lily sponsored symposium:</i>	The ABC's of CDK4/6 inhibitors. Who, When and Why in HR-positive/ HER2-Negative mBC	13.00 -14.30	Alicante Auditorium (Hal 3)
	Poster Discussion - Breast cancer, early stage	14.45 -16.00	Valencia Auditorium (Hal 5)
	Challenges in the management of luminal ER + mBC	16.30 -18.00	Madrid Auditorium (Hal 2)
ZONDAG 29.09.19	Poster Discussion - Breast cancer, metastatic	08.30 -09.50	Cordoba Auditorium (Hal 7)
	Practicing oncology in elderly cancer patients	10:15 -11:45	Alicante Auditorium (Hal 3)

Novartis sponsored symposium:	Tackling the diversity of triple negative early breast cancer (TNBC)	10.15 -11.45	Barcelona Auditorium (Hal 2)
	Optimising Patient Outcomes and Quality of Life in HR+, HER2- ABC	13:00 -14:30	Alicante Auditorium (Hal 3)
	Where will future technologies take us in metastatic breast cancer?	14.45 -16.15	Barcelona Auditorium (Hal 2)
MAANDAG 30.09.19	Treating young patients with BRCA-mutated early breast cancers	08.45 -09.45	Pamplona Auditorium (Hal 2)
Samsung Bioepis sponsored symposium	Quality Assurance to Optimize HER2+ Breast Cancer Treatment	13:00 -14:30	Toledo Auditorium (Hal 5)
	Proffered Paper - Breast cancer, early stage	14.45 -16.15	Bilbao Auditorium (Hal 5)
	Optimal adjuvant and neo-adjuvant therapy in HER-2+ patients	16.30 -18.00	Madrid Auditorium (Hal 2)
DINSDAG 01.10.19	Congress Highlights 1 - The best of ESMO 2019	11.40 -12.20	Madrid Auditorium (Hal 2)

Longkanker

DAG	TITEL	TIJD	LOKATIE
VRIJDAG 27.09.19	Practical use of liquid biopsy for advanced NSCLC	14:15 -15:15	Malaga Auditorium (Hal 5)
	SCLC: Is it time for novel therapies?	14:15 -15:15	Tarragone Auditorium (Hal 7)
	ESMO-ESTRO Collaborative session: RTCT in stage III NSCLC: Prevention and management of toxicity including the use of immunotherapy	14.00 -15.30	Cartagena Auditorium (Hal 3)
	Current markers in immunotherapy	14:00 -15:30	Barcelona auditorium (Hal 2)
	Proffered Paper 1 - NSCLC, metastatic	16.00 -17.30	Barcelona Auditorium (Hal 2)
	Proffered Paper – CNS tumours	16:00 -17:30	Bilbao Auditorium (Hal 5)
<i>Pfizer sponsored symposium:</i>	Pfizer - Real world data in oncology: It's growing role in research and patient care	18:00 -20:00	Alicante Auditorium (Hal 3)
<i>Roche sponsored symposium:</i>	Cracking the Code of Personalised Healthcare	18:00 -20:00	Tarragona auditorium (Hal 7)
ZATERDAG 28.09.19	Poster discussion session – CNS tumours	08:05 - 09:05	Toledo Auditorium (Hal 5)
	Beyond initial radical treatment of patients with lung cancer	08.30 -10.00	Madrid Auditorium (Hal 2)
	Young Oncologist “boxing” session	09:00 -10:30	Santander Auditorium (Hal 3)
	Next immunotherapy strategies for lung cancer	10.15 -11.45	Madrid Auditorium (Hal 2)
	Poster Display Session 1	12:00 -13:00	Poster Area (Hal 4)
	Common but still rare: What happens when common cancers split into subgroups?	13:00 -14:30	Leon Auditorium (Hal 3)
	<i>MSD sponsored symposium:</i> Redefining Survival Expectations in Lung Cancer	13:00 -14:30	Bilbao auditorium (Hal 5)
	<i>BMS sponsored symposium:</i> The Evolving I-O Landscape in NSCLC	13:00 -14:30	Tarragona auditorium (Hal 7)
	Optimal delivery of immune-oncology (I-O) in advanced NSCLC	14:45 -16:15	Madrid Auditorium (Hal2)
	Proffered Paper 1 – Non-metastatic NSCLC and other thoracic malignancies (SCLC)	16.30 -18.00	Cordoba Auditorium (Hal 7)

ZONDAG 29.09.19	Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies	08.30 - 09.50	Sevilla Auditorium (Hall 2)	
	Oligorecurrent and oligoprogressive NSCLC	10:30 -11:30	Bilbao Auditorium (Hal 5)	
	<i>Medscape Oncology sponsored symposium:</i>	Taking the management of stage III NSCLC to the next level: Is your clinic ready?	13:00 -14:30	Pamplona auditorium (Hal 2)
	<i>Boehringer Ingelheim sponsored symposium:</i>	Making First- and Second-Line Treatment Decisions for Advanced NSCLC	13:00 -14:30	Salamanca auditorium (Hal 3)
	Immunotherapy in thoracic malignancies: What has been achieved in 2019?	14.45 -16.15	Sevilla Auditorium (Hal 2)	
	Poster Discussion – NSCLC, metastatic	16.30 -17.45	Cordoba Auditorium (Hal 7)	
MAANDAG 30.09.19	Proffered Paper 2 - NSCLC, metastatic	08.30 -10.00	Madrid Auditorium (Hal 2)	
	How do we personalise treatment in stage III NSCLC	08:45 -09:45	Tarragona auditorium (Hal 7)	
	Poster Display session 3	12:00 -13:00	Poster Area (Hal 4)	
<i>Pfizer sponsored symposium:</i>	EGFR+, ALK+ and ROS1+ NSCLC: More options, right choices	13.00 -14.30	Tarragona Room (Hal 7)	
<i>Roche sponsored symposium:</i>	Right Treatment, Right Time: Improving Outcomes for Patients with Advanced Lung Cancer	13:00 -14:30	Cordoba auditorium (Hal 7)	
<i>AstraZeneca sponsored symposium:</i>	Evolving the Treatment Practice of Advanced EGFRm NSCLC	13:00 -14:30	Bilbao auditorium (Hal 5)	
<i>Illumina sponsored symposium:</i>	Changing paradigms: The benefits of comprehensive genomic profiling	13:00 -14:30	Santander auditorium (Hal 3)	
	The next horizon in metastatic non-small cell targeted therapy	14:45 -16:15	Madrid Auditorium (Hal 2)	
	How to handle comorbidities in the treatment decision of stages	16:30 -18:00	Pamplona Auditorium (Hal 2)	
DINSDAG 01.10.19	<i>Geen sessies voor longkanker</i>	-	-	
	Congress Highlights 2 – The best of ESMO 2019	09:00 -12:40	Sevilla Auditorium (Hal 2)	

Niercelkanker

DAG	TITEL	TIJD	LOCATIE
VRIJDAG 27.09.19	Frontline in mRCC: Ready to select treatment?	16.00 -17.30	Sevilla Auditorium (Hal 2)
<i>Pfizer sponsored symposium:</i>	Pfizer - Real world data in oncology: It's growing role in research and patient care	18:00 -20:00	Alicante Auditorium (Hal 3)
<i>BMS sponsored symposium:</i>	Long-term experience and survival: an overview of I-O therapy in RCC and future research in GU cancers	18:00 -20:00	Bilbao Auditorium (Hal 5)
ZATERDAG 28.09.19	Treatment of the primary tumour in the metastatic setting	16.30 -18.00	Granada Auditorium (Hal 3)
ZONDAG 29.09.19	Specificity of upper tract urothelial carcinoma biology and management	08.45 -09.45	Cartagena Auditorium (Hal 3)
	ESMO Clinical Practice Guidelines 1	9.45 -11.45	Granada Auditorium (Hal 3)
<i>Pfizer/Merck sponsored symposium:</i>	GU 2.0 – Patient care in 2019 and beyond	13.00 -14.30	Tarragona Room (Hal 7)
	ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?	18:30 -20:00	Cordoba Auditorium (Hal 7)
MAANDAG 30.09.19	Selecting and sequencing therapy in previously untreated urothelial cancer	10.15 -11.45	Madrid Auditorium (Hal 2)
DINSDAG 01.10.19	Congress Highlights 1 – The best of ESMO 2019 – GU non-prostate	10.20 -10.40	Madrid Auditorium (Hal 2)